Feature ArticleRadioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor–bearing mice
Section snippets
Synthesis and characterization of GA-AuNPs and GA-198AuNPs
University of Missouri Research Reactor irradiation facilities were used for the production of 198Au. The radioactive and nonradioactive GA-conjugated AuNPs were synthesized using synthetic procedures already established in our laboratory.31, 41 Briefly, H198AuCl4 in 0.05 M HCl was added to aqueous solutions of GA followed by the addition of trimeric alanine conjugate, P(CH2NHCH(CH3)COOH)3. The color change from yellow to a red-purple was observed to yield nanoparticles stabilized by GA. The
Synthesis and characterization of GA-198AuNPs
The synthesis and characterization of GA-198AuNPs and GA-AuNPs were performed by following the procedure established in our laboratory.31, 41. Physicochemical properties such as size, charge, and morphology of GA-AuNPs were determined by TEM and DLS. TEM images of GA-AuNPs indicate that the nanoparticles are spherical with core size range of 12–18 nm. DLS measurements revealed that GA-AuNPs have the hydrodynamic diameter of 85 nm; these data suggest that AuNPs are wrapped with glycoprotein
Discussion
As part of our long-standing interest in the development of nanoparticle-based therapeutic agents, synthetic protocols for stabilizing AuNPs via labeling with biocompatible vectors (including GA glycoprotein) have been optimized.31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 46, 47, 48, 51 Traditional methods use NaBH4 (and other reducing chemicals) for the production of AuNPs at macroscopic levels. However, such methods fail when used at tracer levels to produce 198Au nanoparticulate
References (52)
- et al.
PSA and new biomarkers within multivariate models to improve early detection of prostate cancer
Cancer Lett
(2007) - et al.
Trends in diagnosis of stage T1a-b prostate cancer
J Urol
(1997) Radiation therapy for pancreatic cancer: eleven year experience at the JCRT
Int J Radiat Oncol Biol Phys
(1985)- et al.
Reduction of radiotherapy-induced late complications in early breast cancer: the role of intensity-modulated radiation therapy and partial breast irradiation. Part II—Radiotherapy strategies to reduce radiation-induced late effects
Clin Oncol (R Coll Radiol)
(2005) - et al.
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery
Biomaterials
(2007) - et al.
Biological properties of "naked" metal nanoparticles
Adv Drug Deliv Rev
(2008) - et al.
Fabrication of {198Au0} radioactive composite nanodevices and their use for nanobrachytherapy
Nanomedicine Nanotechnol Biol Med
(2008) - et al.
Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine
Nanomedicine
(2009) Cancer facts and figures 2009–2010
(2009)- et al.
Clinically localised prostate cancer
BMJ
(2006)
Mortality results from a randomized prostate-cancer screening trial
N Engl J Med
Screening and prostate-cancer mortality in a randomized European study
N Engl J Med
High dose rate and external beam radiotherapy in locally advanced prostate cancer
Am J Clin Oncol
Current status and perspectives of brachytherapy for prostate cancer
Int J Clin Oncol
Brachytherapy for prostate cancer: old concept, new techniques
Bull Cancer
The use of interstitial radiation therapy in the treatment of persistent, localized, and unresectable cancer in children
Cancer
Review of MammoSite brachytherapy: advantages, disadvantages and clinical outcomes
Acta Oncol
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles
Proc Natl Acad Sci U S A
Nanotechnology in the management of prostate cancer
Br J Urol Int
Detection of free prostate specific antigen (fPSA) on a nanoporous gold platform
Analyst
Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells
Int J Oncol
Nanotechnology for cancer diagnostics: promises and challenges
Expert Rev Mol Diagn
Magnetic nanoparticles for drug delivery applications
J Nanosci Nanotechnol
Nanotechnology applications in cancer
Annu Rev Biomed Eng
Nano-oncology: drug delivery, imaging, and sensing
Anal Bioanal Chem
Exploiting nanotechnology to target cancer
Br J Cancer
Cited by (0)
This research was supported by grants from the National Institutes of Health–National Cancer Institute under the Cancer Nanotechnology Platform Program: 5R01CA119412-01, NIH-1R21CA128460-01, NIH-SBIR-Contract No. 241, and University of Missouri Research Board Program: C8761 RB 06-030.